GlassScriptPhysician profile
Lisa Bedford
NPI 1467981779
$7,589.49
in general payments reported to CMS, 2019-2025
29 companies · $1,042 in 2025
The $1,042 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,486 · 2020: $770 · 2021: $428 · 2022: $1,496 · 2023: $1,033 · 2024: $1,335 · 2025: $1,042.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,058 · Education: $351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,058.41 |
| Education | $350.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,529.20 | 2019-2025 | Skyrizi, Rinvoq |
| Genzyme Corporation | $1,265.52 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $841.45 | 2020-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $836.76 | 2019-2025 | Tremfya, Stelara, Simponi |
| Amgen INC. | $453.86 | 2019-2024 | Otezla |
| Incyte Corporation | $424.90 | 2022-2025 | Opzelura |
| Celgene Corporation | $272.56 | 2019 | |
| Lilly USA, LLC | $236.79 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Organogenesis INC. | $209.95 | 2020-2025 | Puraply Wound Matrix |
| Arcutis Biotherapeutics, INC. | $200.53 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $160.49 | 2019-2021 | |
| Galderma Laboratories, L.P. | $131.13 | 2022-2024 | |
| Ucb, INC. | $127.17 | 2021-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $125.80 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $103.79 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $103.43 | 2020-2024 | Ilumya |
| Mallinckrodt Enterprises LLC | $99.06 | 2019 | |
| Allergan, INC. | $97.33 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $62.29 | 2019-2022 | |
| Dermavant Sciences, INC. | $45.69 | 2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $44.59 | 2023-2024 | Sotyktu |
| Leo Pharma INC. | $39.87 | 2025 | Adbry |
| Biofrontera INC. | $38.65 | 2019-2021 | |
| Kyowa Kirin, INC. | $33.77 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.87 | 2023-2024 | Spevigo |
| Fresenius Kabi USA, LLC | $21.06 | 2024 | Idacio |
| Organon LLC | $19.84 | 2024 | |
| Genentech USA, INC. | $18.81 | 2022 | |
| Tactile Systems Technology INC | $13.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Bedford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.